Pharmatest Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Private

  • Employees
  • 23

Employees

  • Latest Deal Type
  • 2ndary - Private

Pharmatest General Information

Description

Provider of preclinical efficacy services intended to help with early, cost-effective drug development procedures. The company's translational research services are offered towards addressing the diseases with unmet clinical needs in therapeutic areas of oncology and skeletal disease models, enabling medical researchers to reduce the number of drug candidate failures in clinical trials.

Contact Information

Formerly Known As
Cell Test Turku
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • Itäinen Pitkäkatu 4C
  • 5th floor
  • 20520 Turku
  • Finland
+358 02
Primary Industry
Other Pharmaceuticals and Biotechnology
Vertical(s)
Corporate Office
  • Itäinen Pitkäkatu 4C
  • 5th floor
  • 20520 Turku
  • Finland
+358 02

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pharmatest Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Secondary Transaction - Private 01-Oct-2022 Completed Pre-Clinical Trials
2. Later Stage VC 13-Jan-2014 Completed Pre-Clinical Trials
1. Later Stage VC 01-Jan-2014 Completed Pre-Clinical Trials
To view Pharmatest’s complete valuation and funding history, request access »

Pharmatest Patents

Pharmatest Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-2711007-A1 4-aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer Inactive 19-Sep-2012
EP-2711009-A1 Compounds for use in treating or preventing primary and metastatic breast and prostate cancer Inactive 19-Sep-2012
EP-2711008-A1 N6,n6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer Inactive 19-Sep-2012
JP-2012505666-A Methods and uses involving nav3 gene abnormalities and abnormal expression of multiple genes Active 20-Oct-2008
JP-5819728-B2 Methods and uses involving nav3 gene abnormalities and abnormal expression of multiple genes Inactive 20-Oct-2008 C12Q1/6886
To view Pharmatest’s complete patent history, request access »

Pharmatest Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pharmatest Acquisitions (2)

Pharmatest’s most recent deal was a Merger/Acquisition with Genolyze. The deal was made on 30-Dec-2009.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Genolyze 30-Dec-2009 Merger/Acquisition Enterprise Systems (Healthcare)
Orthotopix 30-Dec-2009 Merger/Acquisition Discovery Tools (Healthcare)
To view Pharmatest’s complete acquisitions history, request access »

Pharmatest FAQs

  • When was Pharmatest founded?

    Pharmatest was founded in 1998.

  • Where is Pharmatest headquartered?

    Pharmatest is headquartered in Turku, Finland.

  • What is the size of Pharmatest?

    Pharmatest has 23 total employees.

  • What industry is Pharmatest in?

    Pharmatest’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Pharmatest a private or public company?

    Pharmatest is a Private company.

  • What is Pharmatest’s current revenue?

    The current revenue for Pharmatest is .

  • How much funding has Pharmatest raised over time?

    Pharmatest has raised $684K.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process